Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 14/20 | 0.77 |
| ▸ | KDR | P35968 | 1/20 | 0.77 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 3/20 | 0.49 |
| ▸ | FLT3 | P36888 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16990706 | 0.91 | RAF1 (0.62) | RAF1KDRRIPK2MAPK13MAPK14 | |
| SCHEMBL15574569 | 0.88 | KDR (0.58) | RAF1KDRRIPK2DDR2MAPK13 | |
| SCHEMBL13234850 | 0.87 | RAF1 (1.00) | RAF1KDRRIPK2DDR2MAPK13 | |
| SCHEMBL102637 | 0.85 | RAF1 (0.72) | RAF1KDRRIPK2MAPK13MAPK14 | |
| SCHEMBL3550019 | 0.85 | RAF1 (0.71) | RAF1KDRRIPK2MAPK13MAPK14 | |
| SCHEMBL14422914 | 0.83 | RAF1 (0.82) | RAF1KDRRIPK2DDR2MAPK13 | |
| SCHEMBL15574633 | 0.82 | HDAC1 (0.60) | RAF1KDRDDR2MAPK13MAPK14 | |
| SCHEMBL13603463 | 0.82 | KDR (0.57) | RAF1KDRDDR2MAPK13MAPK14 | |
| SCHEMBL13603634 | 0.81 | RAF1 (0.58) | RAF1KDRRIPK2DDR2MAPK13 | |
| SCHEMBL15574419 | 0.81 | DDR2 (0.53) | RAF1KDRRIPK2DDR2MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | claimed |
| EP-2890380-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Merck Patent GmbH (DE) | 2015-07-08 | — | — | EP | claimed |
| WO-2014032755-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-03-06 | — | — | WO | claimed |
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| EP-2890380-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Merck Patent GmbH (DE) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014032755-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | RAF1 3072/4885KDR 404/4885RIPK2 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.